Physician profile
Marshall Posner
NPI 1700847753
$96,082.72
in general payments reported to CMS, 2019-2025
10 companies · $12K in 2025
The $12K reported for 2025 was more than what 83% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,420 · 2020: $14K · 2021: $16K · 2022: $16K · 2023: $15K · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $7,751 · Food and Beverage: $1,138 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,219.50 |
| Travel and Lodging | $7,750.79 |
| Food and Beverage | $1,138.47 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82,543.46 | 2019-2025 | Keytruda, Lenvima, Welireg |
| Coherus Oncology, INC. | $13,100.05 | 2021-2025 | Loqtorzi |
| Caris Mpi, INC. | $355.06 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $67.46 | 2024 | Xt Cdx |
| Ibsa Pharma INC. | $16.69 | 2024 | Flector, Tirosint, Licart |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.